Vividion Therapeutics Begins Phase 2 Colorectal Cancer Trial
The company has dosed the first patient in a clinical study testing VVD-214 in combination with pembrolizumab.
Updated on Oct. 15, 2026 in Cancer
Live Poll
Do you trust that pharmaceutical companies prioritize patient welfare when rapidly expanding new drug trials?
Vividion Therapeutics, a subsidiary of Bayer AG, has initiated a Phase 2 clinical trial by dosing the first patient with its oral Werner helicase inhibitor, VVD-214. The trial evaluates the drug in combination with pembrolizumab for the treatment of advanced colorectal cancer.
Why it matters
The study aims to determine the efficacy of using VVD-214 in earlier treatment lines for advanced colorectal cancer. By inhibiting the WRN enzyme, the drug is designed to induce lethal DNA damage specifically in cancer cells.
The clinical trial, designated NCT07811193, aims to enroll approximately 140 patients across 21 countries. This approach targets MSI-high tumors, which represent roughly 15 percent of colorectal cancer cases.
The players
Vividion Therapeutics
A biotechnology company that functions as a subsidiary of Bayer AG and specializes in developing novel therapies for cancer and immune diseases.
Bayer AG
A global life sciences company based in Germany that operates in the healthcare and agricultural sectors.
The details
VVD-214 works as an oral inhibitor of Werner helicase, a mechanism intended to target and destroy cancer cells by inducing DNA damage. Researchers are comparing the combination of VVD-214 and pembrolizumab against the performance of pembrolizumab alone.
Timeline
Phase 1a study results were presented at the AACR in 2025.
The first patient in the Phase 2 trial was dosed on October 15, 2026.
Health Landscape
This trial contributes to the ongoing advancement of the WRN inhibitor drug development pathway within clinical oncology. It marks a significant shift by investigating targeted DNA-damaging inhibitors in earlier treatment lines for advanced cancer patients.
Patients with advanced colorectal cancer may find new treatment options as the study investigates the combination of VVD-214 with existing therapies. The trial's multi-regional scope increases the likelihood of access for patients located across North America, Latin America, Europe, and Asia.
The takeaway
Targeted inhibitors like VVD-214 represent a specialized approach to inducing DNA damage specifically within tumor cells. Advancements in this area of medicine rely on the successful completion of phase-based clinical trials to validate patient safety and treatment efficacy.
Further reading
For more on the current status of oncology research and clinical studies, visit the Cancer section.
Live Poll
Do you trust that pharmaceutical companies prioritize patient welfare when rapidly expanding new drug trials?
